Project description
Microorganisms-based production of plant-derived therapeutics
Monoterpenoid indole alkaloids (MIAs) are plant metabolites of a broad diversity, with more than 2 000 of them derived from a common precursor. The anti-cancer drugs irinotecan, vinblastine and vincristine represent some of the few established MIA therapeutics on the market. The ultimate goal of the EU-funded MIAMi project is to develop new tools and methodologies to elucidate the complexity of the biosynthetic pathways in plants and optimise their production in microorganisms. The researchers aim to create pathway-based technologies for the discovery of plant-derived therapeutics and their biosynthesis adapted to genetically traceable and sustainable production hosts. It will allow the refactoring and phenotypical characterisation of >1 000 MIA pathways to scale up production in yeasts. The current goal of the project is to deliver three lead MIA chemicals and 15 MIA analogues.
Objective
Plants produce some of the most potent human therapeutics and have been used for millennia to treat illnesses. The monoterpenoid indole alkaloids (MIAs) are plant secondary metabolites that show a remarkable structural diversity and pharmaceutically valuable biological activities with more than 2,000 MIAs derived from the common precursor strictosidine. However, because most MIA chemicals do not have their biosynthetic pathways elucidated and MIA-producing plants are not genetically trackable, MIAs are under-represented in recently introduced medicines. In the consortium for Refactoring of Monoterpenoid Indole Alkaloids in Microbial Cell Factories (MIAMi) our main objective is to develop sustainable microbial production of new human therapies for the benefit of the European biotech industry, human health, and the environment. To do so, MIAMi will i) develop a new approach for MIA biosynthetic pathway discovery in plants founded on supervised learning algorithms based on omics data sampled from > 20 MIA producing plants, ii) contribute to standardisation of bioengineering by development of SOPs for characterisation of > 100 DNA elements for control of gene expression, protein interactions, and sub-cellular localisation, iii) build a public parts repository and Bio-CAD for forward engineering of compartmentalised biosynthetic pathway designs in yeast, and iv) apply automated genome engineering to prototype > 1,000 new-to-nature MIA biosynthetic pathway designs in order to identify robust designs for scale-up microbial MIA production processes, and evaluate the environmental benefits and risks compared to existing value chains. The excellent, interdisciplinary and inter-sectorial consortium will showcase the use of the new approaches and standardised data inventory to produce both commercially available and new-to-market MIAs rauwolscine, tabersonine and alstonine in yeast, and finally test their bioactivity as new cancer and psychosis treatment drug leads.
Fields of science
- natural sciencescomputer and information sciencesartificial intelligencemachine learningsupervised learning
- natural sciencesbiological sciencesgeneticsDNA
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesgeneticsgenomes
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
2800 Kongens Lyngby
Denmark